Fig. 7: Targeting B cells enhances STING agonism in HCC.
Immunotherapy resistance is partly mediated by IL-10-secreting TIM-1+ B cells in murine HCC. Combining immunotherapy with B-cell targeting therapy shows efficacy in murine HCC.
Fig. 7: Targeting B cells enhances STING agonism in HCC. | Nature Communications
